Recommendation of the President – Praluent (alirocumab)
On 25 July 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 95/2025 on the reimbursement of the medicinal product Praluent (alirocumab) under the B.101 drug program. “Treatment of patients with lipid disorders (ICD-10: E78.01, I21, I22, I25)”